Cystic Fibrosis, Asthma Rescue Drug & other chronic obstructive lung diseases
In Phase II Clinical Trials
In Pre-Clinical Development
SolAeroMed is a company dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases. Our lead drug, S-1226, is in Phase II clinical trials designed to demonstrate Proof of Concept.